{"id":"argx-113-with-rhuph20","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL6068571","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ARGX-113 with rHuPH20 is a monoclonal antibody that targets the neonatal Fc receptor (FcRn) to reduce the levels of immunoglobulin G (IgG) in the body.","oneSentence":"Monoclonal antibody targeting the neonatal Fc receptor (FcRn)","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:54:14.801Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency"}]},"trialDetails":[{"nctId":"NCT05681481","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid","status":"TERMINATED","sponsor":"argenx","startDate":"2023-03-22","conditions":"Bullous Pemphigoid","enrollment":64},{"nctId":"NCT04598477","phase":"PHASE3","title":"A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)","status":"TERMINATED","sponsor":"argenx","startDate":"2021-07-15","conditions":"Pemphigus Vulgaris, Pemphigus Foliaceus","enrollment":183},{"nctId":"NCT04073589","phase":"PHASE1","title":"Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects","status":"COMPLETED","sponsor":"argenx","startDate":"2019-07-17","conditions":"Healthy Volunteers","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["efgartigimod with rHuPH20"],"phase":"phase_1","status":"active","brandName":"ARGX-113 with rHuPH20","genericName":"ARGX-113 with rHuPH20","companyName":"argenx","companyId":"argenx","modality":"Biologic","firstApprovalDate":"","aiSummary":"Monoclonal antibody targeting the neonatal Fc receptor (FcRn) Used for Primary immunodeficiency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}